Sign in
4

Changes in Ownership

GeneDx Holdings Corp. Filed Acc 0001689575-26-000026

CHIEF EXECUTIVE OFFICER sold 3,639 shares at $53.77 ($195,669)

  • CHIEF EXECUTIVE OFFICER acquired 6,546 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Stueland Katherine CHIEF EXECUTIVE OFFICER 2026-06-09 Option exercise +6,546 99,762 D: show line 1 in the form
Stueland Katherine CHIEF EXECUTIVE OFFICER 2026-06-09 Sale −3,639 $53.77 $195,669 96,123 D: show line 2 in the form
Open-market sales · 3,639 sh · avg $53.77 · $195,669

Table II: Derivative

Insider Date Transaction Shares Price Value Owned after D/I
Stueland Katherine CHIEF EXECUTIVE OFFICER 2026-06-09 Option exercise · Restricted Stock Unit −6,546 13,094 D: show line 3 in the form
Loading xslF345X06/form4-06112026_080609.xml…